BioPharm International-10-04-2010

BioPharm International, October 2010 Supplement (PDF)

October 2nd 2010

The Evolution of Vaccines

Release and Stability Testing Programs for a Novel Virus-Like Particle Vaccine

ByTravis Sadowski,Steven Pincus,Sarathi Boddapati,Jingning Li

October 2nd 2010

Release testing involves both standard potency assays and unique assays (particle size, NA activity) developed to ensure the physical, chemical, and biological stability of this type of vaccine.

Characterization of Aluminum Hydroxide Gel and Oil-in-Water Emulsion Formulations Containing CpG ODNs

ByRyan C. Anderson,Thomas S. Vedvick,Timothy S. Dutill,James Chesko,Christopher B. Fox,Steven G. Reed

October 2nd 2010

Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).

Sterilizing Filtration of Adjuvanted Vaccines: Ensuring Successful Filter Qualification

ByMartha Folmsbee, PhD,Annelies Onraedt, PhD,Anil Kumar,Jerold M. Martin

October 2nd 2010

Filterability and bacterial retention must be verified very early in process development to ensure successful sterilizing filtration validation.

An Alternative Platform for Rapid Production of Effective Subunit Vaccines

ByJudith A. Appleton,Donna Cassidy-Hanley,Ashot Papoyan,Lucille Gagliardo,Xujie Zhang,Theodore G. Clark,Jyothi Jayaram,Yelena Bisharyan,Paul Colussi

October 2nd 2010

Adjuvant activity can be greatly improved by appropriate formulation of cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG ODNs).